Impact of persistent preformed and de novo donor-specific antibodies detected at 1 year after kidney transplantation on long-term graft survival in Japan: a retrospective study

[1]  D. Gjertson,et al.  Clinical utility of complement‐dependent C3d assay in kidney recipients presenting with late allograft dysfunction , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  Jesmar Buttigieg,et al.  Positive Luminex and negative flow cytometry in kidney transplantation: a systematic review and meta-analysis. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  Helena B. Cazarote,et al.  Anti-HLA Donor-Specific IgG Subclasses and C1q-binding Evolution in Posttransplant Monitoring , 2018, Transplantation direct.

[4]  M. Bots,et al.  Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure. , 2018, Journal of the American Society of Nephrology : JASN.

[5]  M. Mazzali,et al.  Effect of Preformed or De Novo Anti-HLA Antibodies on Function and Graft Survival in Kidney Transplant Recipients , 2018, Annals of transplantation.

[6]  J. Jung,et al.  Impact of pretransplant donor‐specific antibodies on kidney allograft recipients with negative flow cytometry cross‐matches , 2018, Clinical transplantation.

[7]  B. Banas,et al.  Analysis of Luminex-based Algorithms to Define Unacceptable HLA Antibodies in CDC-crossmatch Negative Kidney Transplant Recipients , 2018, Transplantation.

[8]  P. Grimbert,et al.  Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation , 2017, Transplantation.

[9]  A. Lobashevsky,et al.  Immunogenicity of Class I HLA but not preformed low MFI donor specific antibodies correlates with outcomes after first renal transplantation. , 2017, Transplant immunology.

[10]  X. Jouven,et al.  Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. , 2017, Journal of the American Society of Nephrology : JASN.

[11]  B. Meiser,et al.  De novo donor‐specific anti‐HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q‐binding ability , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[12]  A. Moktefi,et al.  C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody‐mediated rejection episode: a retrospective cohort study , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[13]  P. Nickerson,et al.  Evaluation of C1q Status and Titer of De Novo Donor‐Specific Antibodies as Predictors of Allograft Survival , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  X. Jouven,et al.  Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. , 2017, Journal of the American Society of Nephrology : JASN.

[15]  Lili Zhao,et al.  Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation. , 2017, Human immunology.

[16]  A. Loupy,et al.  Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA: The Necker High-Risk Transplant Program , 2017, Transplantation.

[17]  C. Gachet,et al.  Pre‐existing donor‐specific antibodies are detrimental to kidney allograft only when persistent after transplantation , 2017, Transplant international : official journal of the European Society for Organ Transplantation.

[18]  J. Cooper,et al.  Clinical Significance of Pretransplant Donor‐Specific Antibodies in the Setting of Negative Cell‐Based Flow Cytometry Crossmatching in Kidney Transplant Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  B. Kiberd,et al.  De Novo Donor‐Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  A. Cabrita,et al.  Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation. , 2015, Transplant immunology.

[21]  R. Heilman,et al.  De Novo Donor-Specific Human Leukocyte Antigen Antibodies Early After Kidney Transplantation , 2014, Transplantation.

[22]  M. Zeier,et al.  Clinical Relevance of HLA Antibody Monitoring after Kidney Transplantation , 2014, Journal of immunology research.

[23]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[24]  P. Nickerson,et al.  Evolution and Clinical Pathologic Correlations of De Novo Donor‐Specific HLA Antibody Post Kidney Transplant , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  T. Pruett,et al.  Revisiting Traditional Risk Factors for Rejection and Graft Loss After Kidney Transplantation , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  Dominique Charron,et al.  Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. , 2010, Journal of the American Society of Nephrology : JASN.

[27]  T. Fehr,et al.  Donor-Specific Antibody Levels and Three Generations of Crossmatches to Predict Antibody-Mediated Rejection in Kidney Transplantation , 2010, Transplantation.

[28]  J. Steiger,et al.  Clinical Relevance of Pretransplant Donor-Specific HLA Antibodies Detected by Single-Antigen Flow-Beads , 2009, Transplantation.

[29]  F. Cosio,et al.  Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.